Old Web
English
Sign In
Acemap
>
authorDetail
>
Mark Shapiro
Mark Shapiro
Roswell Park Cancer Institute
Neutropenia
Calicheamicin
Medicine
Chemotherapy
Inotuzumab ozogamicin
3
Papers
337
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
2010
Journal of Clinical Oncology
Anjali S. Advani
Bertrand Coiffier
Myron S. Czuczman
Martin Dreyling
James M. Foran
Eva Giné
Christian Gisselbrecht
Nicolas Ketterer
Sunita D. Nasta
Ama Rohatiner
Ingo G.H. Schmidt-Wolf
Martin Schuler
Jorge Sierra
Mitchell R. Smith
Gregor Verhoef
Jane N. Winter
Joseph Boni
Erik Vandendries
Mark Shapiro
Luis Fayad
Show All
Source
Cite
Save
Citations (275)
Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study
2008
Blood
Luis Fayad
Hemant Patel
Gregor Verhoef
Mitchell R. Smith
Peter Johnson
Myron S. Czuczman
B Coiffier
Georg Hess
Eva Giné
Anjali S. Advani
Fritz Offner
Erik Vandendries
Mark Shapiro
Nam H. Dang
Show All
Source
Cite
Save
Citations (30)
Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.
2006
Blood
Luis Fayad
Hemant Patel
Gregor Verhoef
Myron S. Czuczman
James M. Foran
Eva Giné
Ama Rohatiner
Mitchell R. Smith
Mark Shapiro
Anjali S. Advani
Show All
Source
Cite
Save
Citations (32)
1